Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer

NCT02571725 is registered in ClinicalTrials.gov with New Mexico Cancer Research Alliance as lead sponsor.

NCT NCT02571725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02571725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Lead sponsor
New Mexico Cancer Research Alliance
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 23, 2016
Completion date
July 15, 2027
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, peritoneal neoplasms